AR and breast cancer: Corey Speers from the University of Michigan, Ann Arbor, USA, and colleagues characterized the radiation sensitivity of 21 breast cancer cell lines and then paired the response data with the findings of a high-throughput drug screen to identify a medication called bicalutamide — an AR inhibitor — as one of the most potent agents for overcoming radiation resistance.